ENDO 2024. New findings suggest GLP-1RAs and SGLT-2is may be more beneficial than other diabetes agents for patients with T2D and MASLD.
Your daily dose of the clinical news you may have missed.
DDW 2024. Offspring with both parents with overweight had a nearly 3-fold increased risk of MASLD in young adulthood, according to new data.
DDW 24. New research shows patients with MASLD and T2D who used GLP-1 agonists had a reduced risk of progression to cirrhosis and HCC vs non-users.
Following the landmark FDA approval of resmetirom for MASH with fibrosis, hepatologist and researcher Alkhouri describes more mid- and late-stage candidates.
Hepatologist Naim Alkhouri, MD, offered 3 take-home thoughts for primary care colleagues to help increase early detection of MASLD.
Naim Alkhouri, MD, a transplant hepatologist and a resmetirom investigator, talks here about the life-changing impact the drug will have for all touched by MASH.
Primary care is where early detection and treatment of liver disease should begin and as Dr Alkhouri highlights here, all the right tools are already at hand.
The national study on the true prevalence of metabolic dysfunction-associated liver disease is essential to screening, prevention, and treatment efforts, says AFL CEO Stiehl.
Alkhouri, a veteran investigator in the field of hepatic disease, including MASLD and MASH, stresses the need for early detection of MASLD when simple intervention can be effective.